BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 8394847)

  • 1. Behavioral effects of a synthetic corticotropin 4-9 analog in patients with depression and patients with Alzheimer's disease.
    Heuser I; Heuser-Link M; Gotthardt U; Grasser A; Holsboer F
    J Clin Psychopharmacol; 1993 Jun; 13(3):171-4. PubMed ID: 8394847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial.
    Künzel HE; Ackl N; Hatzinger M; Held K; Holsboer-Trachsler E; Ising M; Kaschka W; Kasper S; Konstantinidis A; Sonntag A; Uhr M; Yassouridis A; Holsboer F; Steiger A
    J Psychiatr Res; 2009 Apr; 43(7):702-10. PubMed ID: 19038406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
    J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of music therapy on anxiety and depression for patients with Alzheimer's disease and on the burden felt by the main caregiver (feasibility study)].
    Guetin S; Portet F; Picot MC; Defez C; Pose C; Blayac JP; Touchon J
    Encephale; 2009 Feb; 35(1):57-65. PubMed ID: 19250995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lisuride treatment of Alzheimer's disease. A preliminary placebo-controlled clinical trial of safety and therapeutic efficacy.
    Claus JJ; de Koning I; van Harskamp F; Breteler MM; Voet B; Gutzmann H; Dahlke F; van der Cammen T; Hofman A
    Clin Neuropharmacol; 1998; 21(3):190-5. PubMed ID: 9617511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.
    Paleacu D; Barak Y; Mirecky I; Mazeh D
    Int J Geriatr Psychiatry; 2008 Apr; 23(4):393-400. PubMed ID: 17879256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
    Canal N; Imbimbo BP
    Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
    Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression.
    Bech P; Tanghøj P; Andersen HF; Overø K
    Psychopharmacology (Berl); 2002 Aug; 163(1):20-5. PubMed ID: 12185396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease.
    Monji A; Takita M; Samejima T; Takaishi T; Hashimoto K; Matsunaga H; Oda M; Sumida Y; Mizoguchi Y; Kato T; Horikawa H; Kanba S
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):308-11. PubMed ID: 19138715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An ACTH 4-9 analog (Org 2766) and cognitive performance: high-dose efficacy and safety in dementia of the Alzheimer's type.
    Miller TP; Fong K; Tinklenberg JR
    Biol Psychiatry; 1993 Feb; 33(4):307-9. PubMed ID: 8386005
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Alzheimer's disease with a synthetic ACTH 4-9 analog.
    Soininen H; Koskinen T; Helkala EL; Pigache R; Riekkinen PJ
    Neurology; 1985 Sep; 35(9):1348-51. PubMed ID: 2991817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.